1,287,595 injuries reported after COVID shots
1,287,595 injuries reported after COVID shotsFollow @KnightsTempOrg
The Centers for Disease Control and Prevention (CDC) released new data June 3, showing a total of 1,287,595 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and May 27, 2022, to the Vaccine Adverse Event Reporting System (VAERS). That’s an increase of 9,615 adverse events over the previous week.
VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.
The data included a total of 28,532 reports of deaths — an increase of 220 over the previous week — and 235,041 serious injuries, including deaths, during the same time period — up 2,347 compared with the previous week.
Excluding “foreign reports” to VAERS, 825,454 adverse events, including 13,150 deaths and 83,454 serious injuries, were reported in the U.S. between Dec. 14, 2020, and May 27, 2022.
Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.
Of the 13,150 U.S. deaths reported as of May 27, 16% occurred within 24 hours of vaccination, 20% occurred within 48 hours of vaccination and 59% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.
In the U.S., 586 million COVID-19 vaccine doses had been administered as of May 27, including 346 million doses of Pfizer, 221 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).
Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.
Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.
U.S. VAERS data from Dec. 14, 2020, to May 27, 2022, for 5- to 11-year-olds show:
10,958 adverse events, including 291 rated as serious and 5 reported deaths.
22 reports of myocarditis and pericarditis (heart inflammation). The CDC uses a narrowed case definition of “myocarditis,” which excludes cases of cardiac arrest, ischemic strokes and deaths due to heart problems that occur before one has the chance to go to the emergency department. The Defender has noticed over previous weeks that reports of myocarditis and pericarditis have been removed by the CDC from the VAERS system in this age group. No explanation was provided.
43 reports of blood clotting disorders.
U.S. VAERS data from Dec. 14, 2020, to May 27, 2022, for 12- to 17-year-olds show:
31,858 adverse events, including 1,833 rated as serious and 44 reported deaths. VAERS reported 44 deaths in the 12- to 17-year-old age group last week.
62 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases attributed to Pfizer’s vaccine. VAERS reported 63 reports in the 12- to 17-year-old age group last week.
654 reports of myocarditis and pericarditis with 642 cases attributed to Pfizer’s vaccine.
167 reports of blood clotting disorders with all cases attributed to Pfizer. VAERS reported 168 cases of blood clotting disorders in the 12- to 17-year-old age group last week.
U.S. VAERS data from Dec. 14, 2020, to May 27, 2022, for all age groups combined, show:
20% of deaths were related to cardiac disorders.
54% of those who died were male, 41% were female and the remaining death reports did not include the gender of the deceased.
The average age of death was 73.
As of May 27, 5,559 pregnant women reported adverse events related to COVID-19 vaccines, including 1,740 reports of miscarriage or premature birth.
Of the 3,617 cases of Bell’s Palsy reported, 51% were attributed to Pfizer vaccinations, 40% to Moderna and 8% to J&J.
883 reports of Guillain-Barré syndrome, with 42% of cases attributed to Pfizer, 30% to Moderna and 28% to J&J.
2,294 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
1,722 reports of myocardial infarction.
14,064 reports of blood-clotting disorders in the U.S. Of those, 6,294 reports were attributed to Pfizer, 5,032 reports to Moderna and 2,699 reports to J&J.
4,213 cases of myocarditis and pericarditis with 2,583 cases attributed to Pfizer’s, 1,431 cases to Moderna’s and 185 cases to J&J’s COVID-19 vaccines.
Young males have highest risk of heart damage from COVID vaccines
Young males are more likely to report heart damage following vaccination with an mRNA COVID-19 vaccine, and the damage is more likely to be reported after the second dose, according to researchers who reviewed the scientific literature and vaccine injury databases in the U.K., E.U. and U.S.
Research published May 25 in The BMJ showed 18,204 reports of myocarditis and pericarditis were submitted to U.K., U.S. and EU regulators during the study period, beginning when the mRNA vaccines first rolled out until mid-March 2022.
In the U.S., 2,986 events following Pfizer’s vaccine and 1,640 events following Moderna’s vaccine were reported to VAERS.
According to the CDC, 124.12 million people were fully vaccinated with Pfizer and 75.57 million people fully vaccinated with Moderna during the study period.
For Pfizer, the reporting rate was 14.70 cases of myocarditis and 9.36 cases of pericarditis per 1 million fully vaccinated individuals. The combined rate of myocarditis and pericarditis is 12.03 cases reported per 1 million fully vaccinated individuals.
For Moderna, there were 12.35 cases of myocarditis and 9.36 cases of pericarditis reported per 1 million fully vaccinated recipients. The combined reporting rate of both myocarditis and pericarditis is 10.86 per 1 million.
There were 13,573 events of myocarditis and/or pericarditis reported in observational studies included in the systematic review of the literature, but these cannot help to calculate the overall rate of these adverse events.